BACKGROUND: Tuberculosis (TB) risk varies among different HIV subgroups, potentially impacting intensified case finding (ICF) performance. We evaluated the performance of the current ICF algorithm [symptom screening, followed by Xpert MTB/RIF (Xpert) testing] in 2 HIV subgroups and evaluated whether ICF performance could be improved if TB screening was based on C-reactive protein (CRP) concentrations. METHODS: We enrolled consecutive adults with CD4 counts ≤350 cells/µL initiating antiretroviral therapy and performed symptom screening, CRP testing using a low-cost point-of-care (POC) assay, and collected sputum for Xpert testing. We compared the yield and efficiency of the current ICF algorithm to POC CRP-based ICF among patients new to HIV care and patients engaged in care. RESULTS: Of 1794 patients, 126/1315 (10%) new patients and 21/479 (4%) engaged patients had Xpert-positive TB. The current ICF algorithm detected ≥98% of all TB cases in both subgroups but required ≥85% of all patients to undergo Xpert testing. POC CRP-based ICF halved the proportion of patients in both subgroups requiring Xpert testing relative to the current ICF algorithm and had lower yield among patients engaged in care [81% vs. 100%, difference -19% (95% confidence interval: -41 to 3)]. Among patients new to care, POC CRP-based ICF had similar yield as the current ICF algorithm [93% vs. 98%, difference -6% (95% confidence interval: -11 to 0)]. CONCLUSIONS: Among patients new to care, POC CRP-based screening can improve ICF efficiency without compromising ICF yield, whereas symptom-based screening may be necessary to maximize ICF yield among patients engaged in care.
BACKGROUND:Tuberculosis (TB) risk varies among different HIV subgroups, potentially impacting intensified case finding (ICF) performance. We evaluated the performance of the current ICF algorithm [symptom screening, followed by Xpert MTB/RIF (Xpert) testing] in 2 HIV subgroups and evaluated whether ICF performance could be improved if TB screening was based on C-reactive protein (CRP) concentrations. METHODS: We enrolled consecutive adults with CD4 counts ≤350 cells/µL initiating antiretroviral therapy and performed symptom screening, CRP testing using a low-cost point-of-care (POC) assay, and collected sputum for Xpert testing. We compared the yield and efficiency of the current ICF algorithm to POC CRP-based ICF among patients new to HIV care and patients engaged in care. RESULTS: Of 1794 patients, 126/1315 (10%) new patients and 21/479 (4%) engaged patients had Xpert-positive TB. The current ICF algorithm detected ≥98% of all TB cases in both subgroups but required ≥85% of all patients to undergo Xpert testing. POC CRP-based ICF halved the proportion of patients in both subgroups requiring Xpert testing relative to the current ICF algorithm and had lower yield among patients engaged in care [81% vs. 100%, difference -19% (95% confidence interval: -41 to 3)]. Among patients new to care, POC CRP-based ICF had similar yield as the current ICF algorithm [93% vs. 98%, difference -6% (95% confidence interval: -11 to 0)]. CONCLUSIONS: Among patients new to care, POC CRP-based screening can improve ICF efficiency without compromising ICF yield, whereas symptom-based screening may be necessary to maximize ICF yield among patients engaged in care.
Authors: G Henostroza; J B Harris; R Chitambi; M Siyambango; E R Turnbull; K R Maggard; A Krüüner; N Kapata; S E Reid Journal: Int J Tuberc Lung Dis Date: 2016-08 Impact factor: 2.373
Authors: Adrienne E Shapiro; Ting Hong; Sabina Govere; Hilary Thulare; Mahomed-Yunus Moosa; Afton Dorasamy; Carole L Wallis; Connie L Celum; Jacques Grosset; Paul K Drain Journal: AIDS Date: 2018-08-24 Impact factor: 4.177
Authors: C Yoon; L H Chaisson; S M Patel; I E Allen; P K Drain; D Wilson; A Cattamanchi Journal: Int J Tuberc Lung Dis Date: 2017-09-01 Impact factor: 2.373
Authors: Elvin H Geng; Mwebesa B Bwana; Winnie Muyindike; David V Glidden; David R Bangsberg; Torsten B Neilands; Ingrid Bernheimer; Nicolas Musinguzi; Constantin T Yiannoutsos; Jeffrey N Martin Journal: J Acquir Immune Defic Syndr Date: 2013-06-01 Impact factor: 3.731
Authors: Serena P Koenig; Cynthia Riviere; Paul Leger; Patrice Joseph; Patrice Severe; Kea Parker; Sean Collins; Erin Lee; Jean W Pape; Daniel W Fitzgerald Journal: Clin Infect Dis Date: 2009-03-15 Impact factor: 9.079
Authors: Christina Yoon; J Lucian Davis; Laurence Huang; Conrad Muzoora; Helen Byakwaga; Colin Scibetta; David R Bangsberg; Payam Nahid; Fred C Semitala; Peter W Hunt; Jeffrey N Martin; Adithya Cattamanchi Journal: J Acquir Immune Defic Syndr Date: 2014-04-15 Impact factor: 3.731
Authors: Eyongetah Tabenyang Mbu; Florian Sauter; Alexander Zoufaly; Barend M de C Bronsvoort; Kenton L Morgan; Jürgen Noeske; Jean-Louis Foe Abena; Melissa S Sander Journal: PLoS One Date: 2018-06-26 Impact factor: 3.240
Authors: Kenneth Turinawe; Greet Vandebriel; David W Lowrance; Francois Uwinkindi; Philippe Mutwa; Kimberly R Boer; Grace Mutembayire; David Tugizimana; Sabin Nsanzimana; Eric Pevzner; Andrea A Howard; Michel Gasana Journal: PLoS One Date: 2016-09-29 Impact factor: 3.240
Authors: Lelia H Chaisson; Fred C Semitala; Sandra Mwebe; Jane Katende; Lucy Asege; Martha Nakaye; Alfred O Andama; Elly Atuhumuza; Moses Kamya; Adithya Cattamanchi; Christina Yoon Journal: AIDS Date: 2022-06-22 Impact factor: 4.632
Authors: Adrienne E Shapiro; Jennifer M Ross; Mandy Yao; Ian Schiller; Mikashmi Kohli; Nandini Dendukuri; Karen R Steingart; David J Horne Journal: Cochrane Database Syst Rev Date: 2021-03-23
Authors: Fred C Semitala; Lelia H Chaisson; David W Dowdy; Derek T Armstrong; Bishop Opira; Kyomugisha Aman; Moses Kamya; Patrick P J Phillips; Christina Yoon Journal: Trials Date: 2022-05-12 Impact factor: 2.728